Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $40.94 in the prior trading day, Cg Oncology Inc (NASDAQ: CGON) closed at $39.75, down -2.91%. In other words, the price has decreased by -$2.91 from its previous closing price. On the day, 0.93 million shares were traded. CGON stock price reached its highest trading level at $41.64 during the session, while it also had its lowest trading level at $39.5.
Ratios:
Our goal is to gain a better understanding of CGON by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.74 and its Current Ratio is at 22.79. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 11, 2025, initiated with a Outperform rating and assigned the stock a target price of $70.
On October 08, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.Guggenheim initiated its Buy rating on October 08, 2025, with a $90 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when POST LEONARD E sold 1,000 shares for $41.43 per share. The transaction valued at 41,430 led to the insider holds 0 shares of the business.
POST LEONARD E sold 1,000 shares of CGON for $43,250 on Oct 13 ’25. The Director now owns 0 shares after completing the transaction at $43.25 per share. On Oct 09 ’25, another insider, Mulay James, who serves as the Director of the company, sold 5,903 shares for $43.99 each. As a result, the insider received 259,673 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 3206480384 and an Enterprise Value of 2533458688. For the stock, the TTM Price-to-Sale (P/S) ratio is 1477.64 while its Price-to-Book (P/B) ratio in mrq is 4.52. Its current Enterprise Value per Revenue stands at 1165.344 whereas that against EBITDA is -14.112.
Stock Price History:
The Beta on a monthly basis for CGON is 1.37, which has changed by 0.3987018 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $46.01, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is -5.15%, while the 200-Day Moving Average is calculated to be 29.67%.
Shares Statistics:
The stock has traded on average 931.04K shares per day over the past 3-months and 750750 shares per day over the last 10 days, according to various share statistics. A total of 78.28M shares are outstanding, with a floating share count of 50.68M. Insiders hold about 37.18% of the company’s shares, while institutions hold 76.88% stake in the company. Shares short for CGON as of 1764288000 were 13713699 with a Short Ratio of 14.73, compared to 1761868800 on 12477457. Therefore, it implies a Short% of Shares Outstanding of 13713699 and a Short% of Float of 17.940001.
Earnings Estimates
. The current assessment of Cg Oncology Inc (CGON) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.57 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.8 and -$2.24 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$2.54, with 12.0 analysts recommending between -$1.36 and -$3.33.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for CGON’s current fiscal year. The highest revenue estimate was $9.45M, while the lowest revenue estimate was $1.7M, resulting in an average revenue estimate of $2.7M. In the same quarter a year ago, actual revenue was $1.14M
